LDL-C降低对糖尿病血运重建患者心血管结局的影响
该研究 pooled 分析了3项随机临床试验中4050例冠心病合并2型糖尿病患者,按随机化后1年LDL-C水平分组,随访中位3.9年。1年LDL-C≥100 mg/dl者4年MACCE累积风险高于70-<100 mg/dl和<70 mg/dl组;与单纯优化药物治疗相比,仅1年LDL-C<70 mg/dl者PCI与MACCE降低相关,而CABG在各LDL-C分层均与结局改善相关。
要点
- 1年LDL-C≥100 mg/dl者4年MACCE风险显著高于更低LDL-C组。
- 仅当1年LDL-C<70 mg/dl时,PCI较单纯优化药物降低MACCE。
- CABG在各1年LDL-C分层均与结局改善相关。在1年LDL-C≥70 mg/dl者中,CABG的MACCE率显著低于PCI。
核心结论
- 冠心病合并T2DM患者中,1年LDL-C较低与长期MACCE改善相关。
- 与单纯优化药物相比,PCI仅在1年LDL-C<70 mg/dl时与MACCE降低相关。
- CABG在各1年LDL-C分层均与结局改善相关,且在1年LDL-C≥70 mg/dl者中MACCE率显著低于PCI。
研究设计与样本
- 患者水平 pooled 分析,纳入3项随机临床试验。
- 研究对象为冠心病合并2型糖尿病且接受PCI、CABG或单纯优化药物治疗的患者。
- 按随机化后1年LDL-C水平分组,共4050例,中位随访3.9年(自1年评估起)。
主要发现
- 1年LDL-C≥100 mg/dl者4年MACCE累积风险为17.2%,高于70-<100 mg/dl组的13.3%和<70 mg/dl组的13.1%(p=0.016)。
- 与单纯优化药物相比,PCI组仅1年LDL-C<70 mg/dl时MACCE降低(HR 0.61,95%CI 0.40-0.91,p=0.016)。
- CABG在各1年LDL-C分层均与结局改善相关。
- 1年LDL-C≥70 mg/dl者中,CABG的MACCE率显著低于PCI。
关键数值与推荐
- 主要终点MACCE为全因死亡、非致死性心肌梗死和非致死性卒中的复合终点。
- 1年LDL-C分组阈值:<70 mg/dl、70-<100 mg/dl、≥100 mg/dl。
临床怎么用
- 冠心病合并T2DM患者血运重建后应关注1年LDL-C达标情况。
- 若考虑PCI,应力争将1年LDL-C降至<70 mg/dl以可能获得MACCE降低。
- 对于1年LDL-C≥70 mg/dl者,CABG可能较PCI提供更优的MACCE结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated low-density lipoprotein cholesterol (LDL-C) is associated with increased cardiovascular events, especially in high-risk populations. OBJECTIVES: This study sought to evaluate the influence of LDL-C on the incidence of cardiovascular events either following a coronary revascularization procedure (percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]) or optimal medical therapy alone in patients with established coronary heart disease and type 2 diabetes (T2DM). METHODS: Patient-level pooled analysis of 3 randomized clinical trials was undertaken. Patients with T2DM were categorized according to the levels of LDL-C at 1 year following randomization. The primary endpoint was major adverse cardiac or cerebrovascular events ([MACCE] the composite of all-cause mortality, nonfatal myocardial infarction, and nonfatal stroke). RESULTS: A total of 4,050 patients were followed for a median of 3.9 years after the index 1-year assessment. Patients whose 1-year LDL-C remained ≥100 mg/dl experienced higher 4-year cumulative risk of MACCE (17.2% vs. 13.3% vs. 13.1% for LDL-C between 70 and <100 mg/dl and LDL-C <70 mg/dl, respectively; p = 0.016). When compared with optimal medical therapy alone, patients with PCI experienced a MACCE reduction only if 1-year LDL-C was <70 mg/dl (hazard ratio: 0.61; 95% confidence interval: 0.40 to 0.91; p = 0.016), whereas CABG was associated with improved outcomes across all 1-year LDL-C strata. In patients with 1-year LDL-C ≥70 mg/dl, patients undergoing CABG had significantly lower MACCE rates as compared with PCI. CONCLUSIONS: In patients with coronary heart disease with T2DM, lower LDL-C at 1 year is associated with improved long-term MACCE outcome in those eligible for either PCI or CABG. When compared with optimal medical therapy alone, PCI was associated with MACCE reductions only in those who achieved an LDL-C <70 mg/dl.
引用
- Farkouh ME, Godoy LC, Brooks MM, et al. Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization. J Am Coll Cardiol. 2020. PMID: 33153578. doi:10.1016/j.jacc.2020.09.536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。